利培酮联合氟西汀对焦虑抑郁共病患者的治疗观察  

Risperidone combined with Fluoxetine in treatment of depression and anxiety comorbidity

作　　者：钱建军[1] 何炳福[1] 石永扬 高赛男[1] 金海龙[1] 

机构地区：[1]浙江省绍兴市第七人民医院心理科,312000

出　　处：《中国药物与临床》2007年第9期680-681,共2页Chinese Remedies & Clinics

基　　金：浙江省绍兴市科技局基金资助项目(2005193)

摘　　要：目的观察利培酮联合氟西汀对焦虑抑郁共病的疗效和安全性。方法71例焦虑抑郁共病患者随机分为研究组(利培酮+氟西汀)38例、对照组(氟西汀)33例,治疗8周。于治疗前、治疗后每2周测评汉密尔顿抑郁量表(HAMD)24项、汉密尔顿焦虑量表(HAMA)、治疗中需处理的不良反应量表(TESS)。疗效评价以HAMD减分率为标准,不良反应以TESS评分为标准。结果两组HAMD、HAMA评分组间比较从第2周末开始差异有统计学意义(P<0.05、P<0.01),两组疗效比较差异有统计学意义(P<0.05),各时期TESS评分比较差异无统计学意义(P>0.05)。结论利培酮联合氟西汀治疗焦虑抑郁共病的疗效和安全性较好。Objective To observe the efficacy and safety of Risperidone combined with Fluoxetine in treatment of depression and anxiety comorbidity. Methods Seventy-one patients with depression and anxiety comorbidity were randomly divided into the study group （risperidone＋fluoxetine, n=38） and control group （fluoxetine, n=33） to receive therapy as designed for 8 weeks, All patients were assessed with HAMD-24, HAMA and TESS before and every two weeks after initiation of treatment. Results Significant differences in HAMD and HAMA were observed between the two groups starting from week 2 （P〈0.05 and P〈0.01, respectively）, but not in TESS for all times （P〉05）. Conclusion Risperidone combined with fluoxetine showed better efficacy and safety in treatment of deoression and anxietv comorbiditv.

关 键 词：抑郁症 焦虑症 利培酮 氟西汀 

分 类 号：R749.72[医药卫生—神经病学与精神病学] R749.4[医药卫生—临床医学]